 | Up a level |
Back, David, Marzolini, Catia, Hodge, Catherine, Marra, Fiona 
ORCID: 0000-0003-1326-1149, Boyle, Alison, Gibbons, Sara, Burger, David and Khoo, Saye
(2021)
COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87 (1).
pp. 212-213.
Boyle, Alison, Moss, Catherine E ORCID: 0000-0003-2288-7020, Marzolini, Catia and Khoo, Saye ORCID: 0000-0002-2769-0967
(2019)
Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
CLINICAL PHARMACOKINETICS, 58 (12).
pp. 1553-1565.
Hodge, Daryl ORCID: 0000-0003-2288-7020, Marra, Fiona ORCID: 0000-0003-1326-1149, Marzolini, Catia, Boyle, Alison, Gibbons, Sara, Siccardi, Marco ORCID: 0000-0002-3539-7867, Burger, David, Back, David and Khoo, Saye
(2020)
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75 (12).
pp. 3417-3424.
Marra, Fiona ORCID: 0000-0003-1326-1149, Boyle, Alison, Peters, Erica, Morris, Judith, Priest, Matthew, Mcdonald, Natasha and Barclay, Stephen T
(2019)
EFFICACY OF 8 WEEKS GLECAPREVIR/PIBRENTASVIR IN ROUTINE CARE OF PATIENTS WITH CIRRHOSIS AND NON GENOTYPE 3 INFECTION.
.
Boyle, Alison, Marra, Fiona ORCID: 0000-0003-1326-1149, Peters, Erica, Datta, Shouren, Ritchie, Trina, Priest, Matthew, Heydtmann, Mathis and Barclay, Stephen T
(2020)
Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
JOURNAL OF VIRAL HEPATITIS, 27 (4).
pp. 371-375.
Marzolini, Catia, Marra, Fiona, Boyle, Alison, Khoo, Saye ORCID: 0000-0002-2769-0967 and Back, David J
(2022)
Fluvoxamine for the treatment of COVID-19.
LANCET GLOBAL HEALTH, 10 (3).
E331-E331.
Marra, Fiona ORCID: 0000-0003-1326-1149, Smolders, Elise J, El-Sherif, Omar, Boyle, Alison, Davidson, Katherine, Sommerville, Andrew J, Marzolini, Catia, Siccardi, Marco ORCID: 0000-0002-3539-7867, Burger, David, Gibbons, Sara et al (show 2 more authors)
(2021)
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
DRUGS IN R&D, 21 (1).
pp. 9-27.
Marzolini, Catia, Kuritzkes, Daniel R, Marra, Fiona, Boyle, Alison, Gibbons, Sara, Flexner, Charles, Pozniak, Anton, Boffito, Marta, Waters, Laura, Burger, David et al (show 2 more authors)
(2022)
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 112 (6).
pp. 1191-1200.
Marra, Fiona ORCID: 0000-0003-1326-1149, Boyle, Alison, Govender, Chris, Biggart, Lynne, Sills, Laura, Ritchie, Trina and Barclay, Stephen T
(2019)
USING POINT OF CARE TESTING, SIMPLIFIED ASSESSMENT AND MONITORING AND MULTIDISCIPLINARY INITIATION OF TREATMENT TO ELIMINATE HEPATITIS C IN A COMMUNITY ADDICTIONS CLINIC: RESULTS FROM PHASE 1 OF THE SPRINGBURN MICROELIMINATION PROJECT.
.